Primary Progressive Aphasia (PPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Primary Progressive Aphasia (PPA) Market Outlook
Thelansis’s “Primary Progressive
Aphasia (PPA) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Primary Progressive Aphasia (PPA)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Primary Progressive Aphasia (PPA)
Overview
Primary
Progressive Aphasia (PPA) is a neurodegenerative disorder primarily affecting
language abilities. It is classified into three variants based on clinical
characteristics, including logopenic variant PPA (lvPPA), nonfluent agrammatic
PPA (nfaPPA), and semantic variant PPA (svPPA). The symptoms of PPA can vary
and may include difficulty with speech, word finding, comprehension of
language, and naming objects and people. PPA is a result of neurodegeneration,
which refers to the progressive death of brain cells that cannot be attributed
to other causes, such as head trauma, stroke, infection, or cancer. The three
most commonly encountered underlying diseases causing PPA are frontotemporal
lobar degeneration with abnormal TDP-43 accumulation (FTLD-TDP-43),
frontotemporal lobar degeneration with abnormal tau protein accumulation
(FTLD-tau), and Alzheimer’s disease (AD). When abnormal proteins associated
with Alzheimer’s disease or one of the forms of frontotemporal lobar
degeneration (FTLD) attack the brain’s language areas, it results in primary
progressive aphasia (PPA).
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment